Krystal BiotechKRYS
Market Cap: $5.29B
About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Employees: 229
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
40% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 7 (+2) [Q2]
39% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 71
28% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 40
27% more call options, than puts
Call options by funds: $54.5M | Put options by funds: $42.9M
16% more capital invested
Capital invested by funds: $4.52B [Q1] → $5.23B (+$706M) [Q2]
9.83% more ownership
Funds ownership: 89.88% [Q1] → 99.7% (+9.83%) [Q2]
5% more funds holding
Funds holding: 230 [Q1] → 241 (+11) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 20%upside $221 | Buy Reiterated | 29 Aug 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 20%upside $221 | Buy Maintained | 28 Aug 2024 |
Evercore ISI Group Gavin Clark-Gartner 64% 1-year accuracy 7 / 11 met price target | 12%upside $206 | Outperform Maintained | 12 Aug 2024 |
Citigroup Yigal Nochomovitz 40% 1-year accuracy 17 / 42 met price target | 11%upside $204 | Neutral Downgraded | 6 Aug 2024 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 4 / 23 met price target | 13%upside $208 | Buy Maintained | 5 Aug 2024 |
Financial journalist opinion
Based on 4 articles about KRYS published over the past 30 days